elotuzumab
elotuzumab: developed by 1 company · 9 clinical trials tracked · 1 FDA decision.
elotuzumab evidence translation
What we can confirm
1 FDA record · 9 tracked trials
What it means
What to watch
Prepared research question
How could elotuzumab → BMY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 5 study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | Phase 2 |
Clinical Trials (9)
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Primary endpoint: Progression Free Survival (PFS)
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
Primary endpoint: Progression free survival per International Myeloma Working Group criteria
64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
Primary endpoint: Progression Free Survival (PFS)
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
Primary endpoint: Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participants
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Primary endpoint: Progression-free survival (PFS)
LCI-HEM-MYE-CRD-002: A Phase II Study of Carfilzomib- Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Primary endpoint: Number of Participants With VGPR or Better Response to Induction
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Primary endpoint: The number of participants who received at least one dose of elotuzumab or backbone therapy (other study drugs) and the duration of treatment will be collected.
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Primary endpoint: Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Primary endpoint: Phase I: Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Bortezomib, Lenalidomide and Dexamethasone
FDA Decisions1 records
Frequently asked questions
Who is developing elotuzumab?
elotuzumab is being developed by BRISTOL MYERS SQUIBB CO.
How many clinical trials involve elotuzumab?
BioSniper tracks 9 clinical trials involving elotuzumab.
What is elotuzumab's latest FDA decision?
The most recent tracked FDA decision for elotuzumab is Approval for 1 INDICATIONS AND USAGE • EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. EMPLICITI is a SLAMF7-directed immunostimulatory antibody indi, dated November 30, 2015.